Research programme: inflammation therapy - Chiesi USA/Gyre Therapeutics
Alternative Names: Alpha-7 program; Alpha-7 receptor programLatest Information Update: 01 Nov 2023
At a glance
- Originator Critical Therapeutics
- Developer Chiesi USA; Gyre Therapeutics
- Class Small molecules
- Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 30 Oct 2023 GNI has merged with Catalyst Biosciences to form Gyre Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 28 Apr 2014 Cornerstone Therapeutics is now called Chiesi USA